Unraveling the multiple myeloma genome in the next-generation sequencing era: challenges to translating knowledge into the clinic

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

R Fonseca is a consultant for Genzyme, Medtronic, Bristol-Myers Squibb, Amgen, Otsuka, Celgene, Intellikine and Lilly (all less than US$10,000). R Fonseca receives research support from Cylene, Onyx and Celgene. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.